XML 25 R12.htm IDEA: XBRL DOCUMENT
v3.20.2

Equity method and other investments | 9 Months Ended
--- | ---
Sep. 30, 2020
Equity Method Investments and Joint Ventures [Abstract] |
Equity method and other investments | Equity method and other investments The Company maintains equity method and minor adjusted cost method investments in the private securities of certain other healthcare and healthcare-related businesses. The Company classifies these investments as "Equity method and other investments" on its consolidated balance sheet. The Company's equity method and other investments were comprised of the following:
| September 30, 2020 |  | December 31, 2019
APAC joint venture | $ | 124,209 |  |  | $ | 116,924 |
Other equity method partnerships | 110,169 |  |  | 114,611 |
Adjusted cost method investments | 18,105 |  |  | 10,448 |
| $ | 252,483 |  |  | $ | 241,983 |
During the nine months ended September 30, 2020 and 2019, the Company recognized equity investment income of $27,681 and $11,158, respectively, from its equity method investments in nonconsolidated businesses. Equity investments in nonconsolidated businesses over which the Company maintains significant influence, but which do not have readily determinable fair values, are carried on the equity method. The Company's largest equity method investment is its ownership interest in DaVita Care Pte. Ltd. (the APAC joint venture, or APAC JV), which is 75%-owned by the Company and 25%-owned by an unrelated noncontrolling investor. As described in Note 9 to the Company's consolidated financial statements included in the 10-K, the Company does not consolidate the APAC JV. The Company's other equity method investments include legal entities over which the Company has significant influence but in which it does not maintain a controlling financial interest. Almost all of these are U.S. partnerships in the form of limited liability companies. The Company's ownership interests in these partnerships vary, but typically range from 30% to 50%. During the nine months ended September 30, 2020 and 2019, no significant impairments or other valuation adjustments were recognized on these investments.

X
- Definition The entire disclosure for cost method and equity method investments included basis, impairment losses, recognized or unrecognized gains (losses). + References No definition available. + Details
Name: | us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration